Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Phase 1b Study of the Safety, Tolerability, and Preliminary Antitumor Activity of INCB059872 in Participants With Relapsed or Refractory Ewing Sarcoma

NCT03514407 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT03514407
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03514407 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Phase 1b Study of the Safety, Tolerability, and Preliminary Antitumor Activity of INCB059872 in Participants With Relapsed or Refractory Ewing Sarcoma
Lead sponsor
Incyte Corporation
Phase
Phase 1
Overall status
Terminated
Start date
June 27, 2018
Completion date
June 25, 2020
Enrollment
25 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed ewing sarcoma